7 – 10 January, 2019
San Francisco, USA
“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (jpmorgan.com)
10 – 11 December, 2018
ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.
“The 2nd edition I4ID2018, follows the success of the first edition,
4 – 5 December, 2018
ENYO Pharma’s CEO Jacky Vonderscher has been invited to speak in the conference programme of BioFIT 2018 in Lille, France, on December 4th and 5th. He had the opportunity to share his experience and knowledge during the following session – agnostic or pure players in the biotech sector: who is becoming prominent in the early-stage financing rounds? He was also able to give ENYO’s experience feedback following the first fundraising in 2016.
San Francisco, USA
9 – 13 November, 2018
AASLD will see you in San Francisco, where more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world will gather at The Liver Meeting® to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.
4 – 6 July, 2018
ENYO Pharma is proud to announce that a Poster made with Inventiva and Rachel Nechushtai from Hebrew University of Jerusalem will be presented at the 54th edition of the International Conference on Medicinal Chemistry (RICT 2018) in Strasbourg, France on July 4-6, 2018.
RICT will focus on “Interfacing Chemical Biology and Drug Discovery”. The 3-day international congress offers the opportunity to ENYO Pharma to present a novel virus-inspired approach to discover first-in-class preclinical assets for a wide range of therapeutic areas.